Recombinant Anti-PAFAH1B3 antibody [EPR11231-82] - BSA and Azide free (ab249387)
Key features and details
- Produced recombinantly (animal-free) for high batch-to-batch consistency and long term security of supply
- Rabbit monoclonal [EPR11231-82] to PAFAH1B3 - BSA and Azide free
- Suitable for: WB
- Knockout validated
- Reacts with: Human
Related conjugates and formulations
Overview
-
Product name
Anti-PAFAH1B3 antibody [EPR11231-82] - BSA and Azide free
See all PAFAH1B3 primary antibodies -
Description
Rabbit monoclonal [EPR11231-82] to PAFAH1B3 - BSA and Azide free -
Host species
Rabbit -
Tested applications
Suitable for: WBmore details
Unsuitable for: Flow Cyt,ICC/IF,IHC-P or IP -
Species reactivity
Reacts with: Human
Predicted to work with: Mouse, Rat -
Immunogen
Recombinant fragment corresponding to Human PAFAH1B3.
-
Positive control
- WB: HEK293T, Jurkat, HeLa and K-562 cell lysates.
-
General notes
ab249387 is the carrier-free version of ab166906.
Our carrier-free antibodies are typically supplied in a PBS-only formulation, purified and free of BSA, sodium azide and glycerol. The carrier-free buffer and high concentration allow for increased conjugation efficiency.
This conjugation-ready format is designed for use with fluorochromes, metal isotopes, oligonucleotides, and enzymes, which makes them ideal for antibody labelling, functional and cell-based assays, flow-based assays (e.g. mass cytometry) and Multiplex Imaging applications.
Use our conjugation kits for antibody conjugates that are ready-to-use in as little as 20 minutes with <1 minute hands-on-time and 100% antibody recovery: available for fluorescent dyes, HRP, biotin and gold.
This product is compatible with the Maxpar® Antibody Labeling Kit from Fluidigm, without the need for antibody preparation. Maxpar® is a trademark of Fluidigm Canada Inc.
This product is a recombinant monoclonal antibody, which offers several advantages including:
- - High batch-to-batch consistency and reproducibility
- - Improved sensitivity and specificity
- - Long-term security of supply
- - Animal-free production
Our RabMAb® technology is a patented hybridoma-based technology for making rabbit monoclonal antibodies. For details on our patents, please refer to RabMAb® patents.
Properties
-
Form
Liquid -
Storage instructions
Shipped at 4°C. Store at +4°C. Do Not Freeze. -
Storage buffer
pH: 7.2
Constituent: PBS -
Carrier free
Yes -
Concentration information loading...
-
Purity
Affinity purified -
Clonality
Monoclonal -
Clone number
EPR11231-82 -
Isotype
IgG -
Research areas
Associated products
-
Alternative Versions
-
Conjugation kits
-
Isotype control
-
KO cell lines
-
KO cell lysates
-
Positive Controls
-
Recombinant Protein
-
Related Products
Applications
The Abpromise guarantee
Our Abpromise guarantee covers the use of ab249387 in the following tested applications.
The application notes include recommended starting dilutions; optimal dilutions/concentrations should be determined by the end user.
Application | Abreviews | Notes |
---|---|---|
WB |
Use at an assay dependent concentration. Predicted molecular weight: 26 kDa.
|
Notes |
---|
WB
Use at an assay dependent concentration. Predicted molecular weight: 26 kDa. |
Target
-
Function
Inactivates paf by removing the acetyl group at the sn-2 position. This is a catalytic subunit. Plays an important role during the development of brain. -
Tissue specificity
In the adult, expressed in brain, skeletal muscle, kidney, thymus, spleen, colon, testis, ovary and peripheral blood leukocytes. In the fetus, highest expression occurs in brain. -
Sequence similarities
Belongs to the 'GDSL' lipolytic enzyme family. Platelet-activating factor acetylhydrolase IB beta/gamma subunits subfamily. -
Cellular localization
Cytoplasm. - Information by UniProt
-
Database links
- Entrez Gene: 5050 Human
- Entrez Gene: 18476 Mouse
- Entrez Gene: 114113 Rat
- Omim: 603074 Human
- SwissProt: Q15102 Human
- SwissProt: Q61205 Mouse
- SwissProt: O35263 Rat
- Unigene: 466831 Human
see all -
Alternative names
- PA1B3_HUMAN antibody
- PAF acetylhydrolase 29 kDa subunit antibody
- PAF AH 29 kDa subunit antibody
see all
Images
-
All lanes : Anti-PAFAH1B3 antibody [EPR11231-82] (ab166906) at 1/1000 dilution
Lane 1 : Wild-type HEK293T cell lysate
Lane 2 : PAFAH1B3 knockout HEK293T cell lysate
Lane 3 : K-562 cell lysate
Lane 4 : Jurkat cell lysate
Lysates/proteins at 20 µg per lane.
Secondary
All lanes : Goat anti-Rabbit IgG H&L (IRDye® 800CW) preadsorbed (ab216773) at 1/10000 dilution
Predicted band size: 26 kDa
Observed band size: 26 kDaThis data was developed using ab166906, the same antibody clone in a different buffer formulation.
Lanes 1-4: Merged signal (red and green). Green - ab166906 observed at 26 kDa. Red - loading control ab8245 observed at 36 kDa.
ab166906 Anti-PAFAH1B3 antibody [EPR11231-82] was shown to specifically react with PAFAH1B3 in wild-type HEK293T cells. Loss of signal was observed when knockout cell line ab266669 (knockout cell lysate ab258559) was used. Wild-type and PAFAH1B3 knockout samples were subjected to SDS-PAGE. ab166906 and Anti-GAPDH antibody [6C5] - Loading Control (ab8245) were incubated overnight at 4°C at 1 in 1000 dilution and 1 in 20000 dilution respectively. Blots were developed with Goat anti-Rabbit IgG H&L (IRDye® 800CW) preadsorbed (ab216773) and Goat anti-Mouse IgG H&L (IRDye® 680RD) preadsorbed (ab216776) secondary antibodies at 1 in 20000 dilution for 1 hour at room temperature before imaging.
-
All lanes : Anti-PAFAH1B3 antibody [EPR11231-82] (ab166906) at 1/1000 dilution
Lane 1 : K562 cell lysate
Lane 2 : 293T cell lysate
Lane 3 : HeLa cell lysate
Lane 4 : Jurkat cell lysate
Lysates/proteins at 10 µg per lane.
Predicted band size: 26 kDaThis data was developed using ab166906, the same antibody clone in a different buffer formulation.
Protocols
To our knowledge, customised protocols are not required for this product. Please try the standard protocols listed below and let us know how you get on.
Datasheets and documents
-
Datasheet download
Certificate of Compliance
References (0)
ab249387 has not yet been referenced specifically in any publications.